Table S2.
Summary of LC/MS data of unirradiated and irradiated peptide alone, and in purified TABPR/HLA-A2 complex and TAPBPR + HLA/A2 mixture
| Condition | Amount, pmol | Peptide | Elemental composition | Calculated m/z | Elution time | EIC peak area | Observed m/z | Error, ppm | MS signal intensity |
| Peptides with and without irradiation | |||||||||
| Unirradiated | 12 | GILGFVFJL | C54H77N10O12 | 1,057.5717 | 47.4–47.8 | 4.55 e7 | 1,057.5759 | 3.97 | 3.16 e7 |
| Irradiated | 12 | GILGFVFJL | C54H77N10O12 | 1,057.5717 | 47.5–47.8 | 9.32 e5 | 1,057.5750 | 3.12 | 7.89 e5 |
| GILGFVF-NH2 | C39H59N8O7 | 751.4501 | 39.4–39.6 | 7.9 e7 | 751.4521 | 2.66 | 6.22 e7 | ||
| Unirradiated | 25 | GILGFVFJL | C54H77N10O12 | 1,057.5717 | 47.4–47.8 | 1.83 e8 | 1,057.5746 | 2.74 | 1.33 e8 |
| Irradiated | 25 | GILGFVFJL | C54H77N10O12 | 1,057.5717 | 47.5–47.8 | 2.15 e6 | 1,057.5769 | 4.9 | 1.62 e6 |
| GILGFVF-NH2 | C39H59N8O7 | 751.4501 | 39.4–39.6 | 2.24 e8 | 751.4536 | 4.6 | 1.86 e8 | ||
| TABPBPR/HLA-A2 complexes or TAPBPR + HLA-A2 mixture | |||||||||
| Unirradiated | 30 | GILGFVFJL | C54H77N10O12 | 1,057.5717 | 47.05–47.4 | 2.42 e8 | 1,057.5692 | −2.36 | 1.65 e8 |
| Irradiated | 30 | GILGFVFJL | C54H77N10O12 | 1,057.5717 | 47.5–47.8 | 2.59 e6 | 1,055.5526* | — | — |
| GILGFVF-NH2 | C39H59N8O7 | 751.4501 | 39.4–39.6 | 4.24 e7 | 751.4476 | −3.32 | 2.96 e7 | ||
| Unirradiated | 60 | GILGFVFJL | C54H77N10O12 | 1,057.5717 | 46.8–47.2 | 6.32 e8 | 1,057.5696 | −1.98 | 5.42 e8 |
| Irradiated | 60 | GILGFVFJL | C54H77N10O12 | 1,057.5717 | 47–47.4 | 6.74 e6 | 1,055.5536 | — | — |
| GILGFVF-NH2 | C39H59N8O7 | 751.4501 | 39.6–39.9 | 4.68 e7 | 751.4488 | −1.72 | 3.23 e7 | ||
*
We have noticed loss of two hydrogens in the full peptide after irradiation; this can be seen in the reduction by 2 Da in its molecular ion.